Lactobacillus plantarum CCFM1143 Alleviates Chronic Diarrhea via Inflammation Regulation and Gut Microbiota Modulation: A Double-Blind, Randomized, Placebo-Controlled Study

Yang, Bo; Yue, Yue; Chen, Yang; Ding, Mengfan; Li, Bowen; Wang, Linlin; Wang, Qun; Stanton, Catherine; Ross, R. Paul; Zhao, Jianxin; Zhang, Hao

doi:10.3389/fimmu.2021.746585

Cited by 41 publications

(32 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…plantarum CCFM1143 down-regulated pro-inflammatory cytokines such as IFN-γ, TNF-α, and IL-6 [ 39 ]. A trial on chronic diarrhea in humans reported that modulation of intestinal inflammation via IL-6 inhibition improved the symptoms [ 20 ]. Exopolysaccharides from Lp.…”

Section: Discussionmentioning

confidence: 99%

“…L p . plantarum CCFM1143 intake increased Firmicutes and Proteobacteria abundance and decreased Bacteroidetes abundance [ 20 ]. The relative abundance of Lactobacillus and Veillonella (Phyla Firmicutes) was higher while that of Escherichia–Shigella (Phyla Proteobacteria) and Bacteroides (Phyla Bacteroidetes) was lower in the GTB1 group.…”

Section: Discussionmentioning

confidence: 99%

“…Several studies identified the mechanisms of probiotics in IBS treatment. Randomized, placebo-controlled studies on IBS patients have revealed that Lactobacillus and Bifidobacterium are beneficial in this condition [ 17 , 18 , 19 , 20 , 21 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Effect of Oral Intake of Lactiplantibacillus plantarum APsulloc 331261 (GTB1TM) on Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Study

et al. 2022

View full text Add to dashboard Cite

Irritable bowel syndrome (IBS) causes intestinal discomfort, gut dysfunction, and poor quality of life. This randomized, double-blind placebo-controlled trial evaluated the efficacy of Lactiplantibacillus (Lp., formerly Lactobacillus) plantarum APsulloc 331261 (GTB1TM) from green tea leaves in participants with diarrhea-predominant irritable bowel syndrome (IBS-D). Twenty-seven participants meeting the Rome IV diagnostic criteria were randomized for GTB1 or placebo ingestion for four weeks and follow-up for two weeks. The efficacy endpoints included adequate global relief of symptoms, assessment of intestinal discomfort symptom severity and frequency, stool frequency, satisfaction, and fecal microbiome abundance. Of all participants, 94.4% and 62.5% reported global relief of symptoms in the GTB1 and placebo groups, respectively, with significant differences (p = 0.037). GTB1 significantly reduced the severity and frequency of abdominal pain, bloating, and feeling of incomplete evacuation. The frequencies of diarrhea were decreased −45.89% and −26.76% in the GTB1 and placebo groups, respectively (p = 0.045). Hence, GTB1 ingestion improved IBS-D patient quality of life. After four weeks treatment, the relative abundance of Lactobacillus was higher in the GTB1 than in the placebo group (p = 0.010). Our results showed that GTB1 enhanced intestinal discomfort symptoms, defecation consistency, quality of life, beneficial microbiota, and overall intestinal health.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Effect of Oral Intake of Lactiplantibacillus plantarum APsulloc 331261 (GTB1TM) on Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Study

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The probiotic bacterium, Lactobacillus (L.) plantarum which is in generally-recognized-as-safe (GRAS) status according to the US Food and Drug Administration is generally used in food industry applications, including in yogurt, fermented vegetables, and beverages 5,6 . The reported health benefits of L. plantarum is on cholesterol, diarrhea, and irritable bowel syndrome 7 . After growing in glucose or sucrose, L. plantarum strains can produce exopolysaccharides (EPS) 8 .…”

Section: Introductionmentioning

confidence: 99%

Ev yapımı süt ürünlerinden Lactobacillus plantarum ekzopolisakkaritlerinin obezite üzerindeki koruyucu etkileri

Turan

Cadirci

Altun

2022

CMJ

View full text Add to dashboard Cite

Dünyayı etkisi altına alan COVİD 19 pandemisi sırasında evlere kapanmak zorunda kalınması, aşırı hareketsizlik ve yağlı yiyeceklerin tüketimi, insanlara obezite gibi ciddi sağlık sorunu ortaya çıkarmıştır. Probiyotiklerin gastrointestinal (GI) sağlığı destekleme yeteneği yıllardır bilinmektedir. GI sistemine yapılan müdahale ile obeziteye karşı alternatif yaklaşımlar geliştirilebildiğinden, bu çalışmada, probiyotik karakteristiklere sahip doğal ürünlerden izole edilen bir anti-obezite biyomalzemesi olarak ekzopolisakkaritlerin (EPS) etkilerinin değerlendirilmesi amaçlanmıştır. İlk olarak, bilinen probiyotik özelliklere sahip 10 mikroorganizma içerisinden en yüksek EPS miktarına sahip olanı, MALDI-TOF ve 16srRNA dizi analizi ile tanımlanmış ve L. plantrum BHC007 olarak isimlendirilmiştir. Daha sonra, ekstrakte edilen EPS’nin monosakkarit bileşimi incelenmiş ve ortalama moleküler ağırlığı 221,860±0.006 olarak belirlenmiştir. EPS’nin adipogenez süreci üzerindeki etkisi 3T3 hücre hattı üzerinde, Oil Red O boyası ile niteliksel olarak, ayrıca triaçilgliserol (TAG) seviyeleri hücresel olarak incelenmiştir. En yüksek EPS konsantrasyonunun (2.25 mM) adipogenezi %75 inhibe ettiği sonucuna varılmıştır. Ayrıca, en düşük EPS konsantrasyonunda (0.45 mM) %17 adipogenez inhibisyonuna ulaşıldı. Sonuç olarak, TAG analizi EPS’nin lipit damlacık oluşum konsantrasyonuna bağlı olarak baskılandığını ortaya koymuştur.

show abstract

“…Also, the altered metabolism of bile acids (increase in primary BAs and decrease in secondary BAs) in these patients correlated with IBS symptoms such as diarrhea and visceral hypersensitivity. al [15] 2021…”

mentioning

confidence: 99%

The Role of Gut-Microbiota in the Pathophysiology and Therapy of Irritable Bowel Syndrome: A Systematic Review

Shrestha¹,

Patel²,

Shah³

et al. 2022

Cureus

View full text Add to dashboard Cite

Irritable Bowel Syndrome (IBS) is one of the most prevalent chronic gastrointestinal diseases, which is characterized by recurrent abdominal pain and altered bowel habits. The pathophysiological mechanisms are not completely clear for IBS, multiple factors such as genetic, psychosocial, environmental, visceral hypersensitivity, low-grade inflammation, gastrointestinal motility changes, food components, and intestinal microbiota are thought to play a role in the disease process of IBS. The rapid progression of recent microbiome research using advanced microbiological technologies has shed light on dysbiosis related to the pathophysiology of IBS. We used PubMed, PubMed Central, and Medline as our primary databases to search for articles using keywords and medical subject heading (MeSH) keywords on April 30, 2022, to render a total of 4062 articles. Then, a total of 10 articles were selected following a quality assessment. Despite the variable findings in different studies, most studies have concluded that IBS patients have a reduction in bacterial diversity and an increase in the temporal instability of the microbiota. IBS is known as a stress disorder, and the gut-microbiome-brain axis has been associated with the pathogenesis of the disease. Additionally, the potential of dietary manipulation of gut microbiota and the use of probiotics, prebiotics, and synbiotics in the treatment of IBS has been studied in recent years and shown promising results. We concluded that the gut microbiome plays a substantial role in the pathophysiology of IBS.

show abstract

Lactobacillus plantarum CCFM1143 Alleviates Chronic Diarrhea via Inflammation Regulation and Gut Microbiota Modulation: A Double-Blind, Randomized, Placebo-Controlled Study

Cited by 41 publications

References 48 publications

Effect of Oral Intake of Lactiplantibacillus plantarum APsulloc 331261 (GTB1TM) on Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Study

Effect of Oral Intake of Lactiplantibacillus plantarum APsulloc 331261 (GTB1TM) on Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Study

Ev yapımı süt ürünlerinden Lactobacillus plantarum ekzopolisakkaritlerinin obezite üzerindeki koruyucu etkileri

The Role of Gut-Microbiota in the Pathophysiology and Therapy of Irritable Bowel Syndrome: A Systematic Review

Contact Info

Product

Resources

About